Stocks · News reference
These results reinforce AbbVie's scientific expertise in migraine and its focus on advancing solutions for people living with complex and disabling migraine attacks."These positive Phase 3 LUNA results represent
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Iambic Therapeutics, an AI drug discovery company backed by Nvidia and the Qatar Investment Authority, filed to go public Monday.
The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.
An official report on September 18, 2026 reveals Representative Pete Sessions's recent sale of AbbVie (NYSE:ABBV) stock, valued between $30,002 and $100,000. The transaction took place on September 14, 2026, as per
The companies will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug candidates."We are excited about the purpose-built AI capabilities Iambic is bringing to